Stocks and Investing
Stocks and Investing
Wed, August 10, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tiago Fauth Maintained (ABCL) at Buy with Decreased Target to $34 on, Aug 10th, 2022
Tiago Fauth of Credit Suisse, Maintained "AbCellera Biologics Inc." (ABCL) at Buy with Decreased Target from $40 to $34 on, Aug 10th, 2022.
Tiago has made no other calls on ABCL in the last 4 months.
There are 2 other peers that have a rating on ABCL. Out of the 2 peers that are also analyzing ABCL, 0 agree with Tiago's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Tiago
- Do Kim of "Piper Sandler" Maintained at Buy with Increased Target to $22 on, Tuesday, July 26th, 2022
- Puneet Souda of "SVB Leerink" Maintained at Buy with Decreased Target to $14 on, Wednesday, May 11th, 2022
Contributing Sources